ImpediMed’s Strategic Revamp Spurs U.S. Sales Growth
Company Announcements

ImpediMed’s Strategic Revamp Spurs U.S. Sales Growth

Impedimed Limited (AU:IPD) has released an update.

ImpediMed Limited reported a mixed financial year in 2024, with total revenue dipping by 9% to $10.3 million, attributed to the end of a significant Astra Zeneca trial. However, the company’s core SOZO business saw a revenue rise of 14%, alongside an increase in annual recurring revenue and the number of tests conducted. The firm’s renewed commercial strategy and leadership team have led to a notable 77% increase in U.S. unit sales in Q4, indicating a promising turnaround.

For further insights into AU:IPD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskImpedimed Limited Issues Shares to Executives
TipRanks Australian Auto-Generated NewsdeskImpediMed Limited Presents at Major Conference
TipRanks Australian Auto-Generated NewsdeskImpedimed Director Increases Stake with Options Grant
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App